Cited in:


This article has been cited by:

  1. 1
    N. Ben Raïs Aouad, I. Ghfir, F. Missoum, J. Rahali, H. Guerrouj, R. Ksyar, S. Fellah, A. Bssis, I. Ech-Cherraq, Aspects épidémiologiques du cancer différencié de la thyroïde (médullaire exclu) au Maroc, Médecine Nucléaire, 2008, 32, 11, 580


  2. 2
    C. F. A. Eustatia-Rutten, J. W. A. Smit, J. A. Romijn, E. P. M. Van Der Kleij-Corssmit, A. M. Pereira, M. P. Stokkel, J. Kievit, Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis, Clinical Endocrinology, 2004, 61, 1
  3. 3
    Vitale Giovanni, Lupoli Gelsy Arianna, Ciccarelli Antonio, Fonderico Francesco, Klain Michele, Squame Giovanni, Salvatore Marco, Lupoli Giovanni, The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre, Clinical Endocrinology, 2002, 56, 2
  4. 4
    Lester D. R. Thompson, Jacqueline A. Wieneke, Edina Paal, R. Allen Frommelt, Carol F. Adair, Clara S. Heffess, A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature , Cancer, 2001, 91, 3